https://www.selleckchem.com/pr....oducts/Rapamycin.htm
Furthermore, BBR was able to inhibit hepatic fibrosis by modulating the expression of multiple genes involved in hepatic stellate cell activation and cholangiocyte proliferation. Consistent with our previous findings, BBR's beneficial effects are linked with the downregulation of microRNA34a and long noncoding RNA H19, which are two important players in promoting NASH progression and liver fibrosis. Conclusion BBR is a promising therapeutic agent for NASH by targeting multiple pathways. These results provide a strong foundation for a
Like
Comment
Share
